Ipsen's Latest Consumer Health Play: Growth Or Attracting Suitors?
Less than a month after investing in Italian nutritional supplement maker Akkadeas Pharma, Ipsen acquires five Sanofi OTC drug brands marketed in Europe, including Prontalgine analgesics available in France.
You may also be interested in...
Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
France’s Ipsen is preparing to launch Cabometyx in Europe this autumn and telotristat next year, and the business development expertise of its new CEO will be useful in replenishing its product portfolio.